Ahn MJ et al. Durvalumab + olaparib vs durvalumab alone as maintenance therapy in metastatic NSCLC: Outcomes from the phase 2 ORION study. WCLC 2022;Abstract P1.15-11.

Dagogo-Jack I et al. A phase 2 study of capmatinib in patients with MET-altered lung cancer previously treated with a MET inhibitor. J Thorac Oncol 2021;16(5):850-9. Abstract

Krebs M et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. ASCO 2022;Abstract 9008.

Le X et al. Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp). ASCO 2021;Abstract 9021.

Mazieres J et al. Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study. ESMO 2022;Abstract LBA52.

Thai AA et al. Lung cancer. Lancet 2021;398(10299):535-54. Abstract